Key Points
- Insider sale: Lucas Vitale sold 4,269 shares on March 17 at an average price of $11.92 for about $50,886, trimming his stake by 2.59% to 160,449 shares (worth ≈$1.91M).
- Earnings miss: Orthofix reported ($0.06) EPS vs. a $0.44 estimate, showing a negative net margin (-11.21%) and negative ROE (-20.38%) while revenue of $219.9M was roughly in line with expectations.
- Market view: The stock has a $464.2M market cap and a 12-month range of $10.24–$17.00; analysts have a mixed stance (3 Buy, 2 Hold, 1 Sell) with a consensus price target of $17.25 and institutional ownership near 89.8%.
Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) insider Lucas Vitale sold 4,269 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $11.92, for a total value of $50,886.48. Following the completion of the sale, the insider owned 160,449 shares in the company, valued at $1,912,552.08. The trade was a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Orthofix Medical Price Performance
Shares of OFIX opened at $11.57 on Friday. The stock has a market capitalization of $464.22 million, a P/E ratio of -4.94 and a beta of 0.75. Orthofix Medical Inc. has a twelve month low of $10.24 and a twelve month high of $17.00. The company has a 50 day moving average of $13.24 and a 200-day moving average of $14.49. The company has a quick ratio of 1.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.39.
Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The business had revenue of $219.91 million during the quarter, compared to analyst estimates of $218.72 million. As a group, equities research analysts forecast that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.
Hedge Funds Weigh In On Orthofix Medical
Several large investors have recently modified their holdings of the stock. CWM LLC grew its stake in Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company's stock valued at $28,000 after buying an additional 955 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Orthofix Medical during the third quarter worth approximately $30,000. Kestra Advisory Services LLC acquired a new stake in Orthofix Medical during the fourth quarter worth approximately $56,000. Mackenzie Financial Corp bought a new stake in shares of Orthofix Medical during the third quarter worth approximately $148,000. Finally, Strs Ohio acquired a new position in shares of Orthofix Medical in the first quarter valued at approximately $150,000. 89.76% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have commented on OFIX shares. TD Cowen began coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They set a "hold" rating and a $14.00 price target on the stock. Barrington Research dropped their target price on Orthofix Medical from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, February 25th. Wall Street Zen raised Orthofix Medical from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Stifel Nicolaus decreased their price target on Orthofix Medical from $22.00 to $18.00 and set a "buy" rating for the company in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $17.25.
Check Out Our Latest Report on OFIX
About Orthofix Medical
(
Get Free Report)
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
